LT2914255T - Širdies ir kraujagyslių sistemos sutrikimų gydymas arba prevencija, skiriant kolchiciną - Google Patents

Širdies ir kraujagyslių sistemos sutrikimų gydymas arba prevencija, skiriant kolchiciną

Info

Publication number: LT2914255T
Authority: LT; Lithuania
Prior art keywords: collicine; prevention; treatment; cardiovascular disorders; cardiovascular
Prior art date: 2012-11-02

Application number

LTEPPCT/AU2013/001261T

Other languages

English (en)

Inventor

Mark NIDORF

Original Assignee

Murray & Poole Enterprises, Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-02

Filing date

2013-11-01

Publication date

2021-11-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50626218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2914255(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-11-02 Priority claimed from AU2012904828A external-priority patent/AU2012904828A0/en

2013-11-01 Application filed by Murray & Poole Enterprises, Ltd. filed Critical Murray & Poole Enterprises, Ltd.

2021-11-10 Publication of LT2914255T publication Critical patent/LT2914255T/lt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Dermatology (AREA)

LTEPPCT/AU2013/001261T 2012-11-02 2013-11-01 Širdies ir kraujagyslių sistemos sutrikimų gydymas arba prevencija, skiriant kolchiciną LT2914255T (lt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU2012904828A AU2012904828A0 (en)		2012-11-02	Treatment and Prevention of Coronary Thrombosis
AU2012904868A AU2012904868A0 (en)		2012-11-05	Treatment or Prevention of Cardiovascular Events
PCT/AU2013/001261 WO2014066944A1 (en)	2012-11-02	2013-11-01	Treatment or prevention of cardiovascular events via the administration of a colchicine derivative

Publications (1)

Publication Number	Publication Date
LT2914255T true LT2914255T (lt)	2021-11-10

Family

ID=50626218

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEPPCT/AU2013/001261T LT2914255T (lt)	2012-11-02	2013-11-01	Širdies ir kraujagyslių sistemos sutrikimų gydymas arba prevencija, skiriant kolchiciną

Country Status (24)

Country	Link
US (18)	US10265281B2 (lt)
EP (2)	EP3964205A1 (lt)
JP (1)	JP6356684B2 (lt)
KR (7)	KR102858016B1 (lt)
CN (2)	CN104918613B (lt)
AU (5)	AU2013337605B2 (lt)
BR (1)	BR112015010063B1 (lt)
CA (1)	CA2894417C (lt)
CL (1)	CL2015001154A1 (lt)
DK (1)	DK2914255T3 (lt)
EA (1)	EA032515B1 (lt)
ES (1)	ES2900740T3 (lt)
HR (1)	HRP20211644T1 (lt)
HU (1)	HUE056810T2 (lt)
IL (1)	IL238519B (lt)
LT (1)	LT2914255T (lt)
MX (2)	MX393493B (lt)
MY (1)	MY177898A (lt)
NZ (2)	NZ707640A (lt)
PL (1)	PL2914255T3 (lt)
PT (1)	PT2914255T (lt)
SG (2)	SG10201703586PA (lt)
SI (1)	SI2914255T1 (lt)
WO (1)	WO2014066944A1 (lt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN108096209A (zh)	2009-06-15	2018-06-01	阿马里纳制药公司	在相伴他汀类疗法的对象中降低甘油三酯、没有增加ldl-c水平的组合物和方法
MX393493B (es)	2012-11-02	2025-03-21	Murray & Poole Entpr Ltd	Tratamiento o prevención de eventos cardiovasculares.
AU2014255434B2 (en)	2013-04-16	2018-11-08	Murray And Poole Enterprises Limited	Sustained-release formulations of colchicine and methods of using same
EP3283063A1 (en) *	2015-04-17	2018-02-21	Murray And Poole Enterprises Limited	Colchicine salicylate and uses thereof
US9907751B2 (en)	2016-03-10	2018-03-06	RxOMEG Therapeutics LLC	Composition and method of use of colchicine oral liquid
US10226423B1 (en)	2017-12-20	2019-03-12	RxOMEG Therapeutics LLC	Colchicine drug-to-drug interactions
CN111954524A (zh)	2018-02-02	2020-11-17	默里和普尔企业有限公司	秋水仙碱抑制肿瘤生长和转移的用途
KR20250172901A (ko)	2018-06-29	2025-12-09	알버타 헬스 서비시즈	콜히친 유도체의 방법 및 용도
MA51766A (fr)	2018-09-24	2020-12-16	Amarin Pharmaceuticals Ie Ltd	Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
BR112022009189A2 (pt)	2019-11-12	2022-07-26	Amarin Pharmaceuticals Ie Ltd	Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial
KR102112456B1 (ko)	2019-11-13	2020-05-19	주식회사 에이스바이오메드	간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
EP3821889A1 (en) *	2019-11-15	2021-05-19	Institut de Cardiologie de Montréal	Methods for using low-dose colchicine after myocarial infarction
CA3099143A1 (en)	2019-11-15	2021-01-26	Institut De Cardiologie De Montreal	Early administration of low-dose colchicine after myocardial infarction
CA3161620A1 (en)	2019-11-15	2021-05-20	Institut De Cardiologie De Montreal	Methods for using low-dose colchicine after myocardial infarction
KR102150821B1 (ko)	2020-01-22	2020-09-03	주식회사 에이스바이오메드	간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR20210095249A (ko)	2020-01-22	2021-08-02	주식회사 에이스바이오메드	간 질환 치료용 또는 치료 효과 증진을 위한 콜히친 복합제제
KR102177781B1 (ko)	2020-04-27	2020-11-12	주식회사 에이스바이오메드	간 질환 치료용 또는 치료 효과 증진을 위한 콜히친, 우르소데옥시콜산 및 비페닐디메틸디카르복실레이트의 복합제제
US20240075045A1 (en) *	2020-12-15	2024-03-07	Romeg Therapeutics Llc	Methods and compositions for treating pericarditis
WO2022212655A1 (en) *	2021-03-31	2022-10-06	Amarin Pharmaceuticals Ireland Limited	Compositions comprising epa and colchicine and methods of using the same for reducing the risk of cardiovascular events in a subject
US11986452B2 (en)	2021-04-21	2024-05-21	Amarin Pharmaceuticals Ireland Limited	Methods of reducing the risk of heart failure
CN114656429A (zh) *	2021-11-18	2022-06-24	江苏新元素医药科技有限公司	一类抗炎镇痛化合物及其用途
WO2024224234A1 (en) *	2023-04-23	2024-10-31	Vishal Kumar	Pharmaceutical composition in powder form in sachets and tablet of 90 mg ticagrelor + 20 mg rosuvastatin
CN118717741A (zh) *	2024-01-15	2024-10-01	华中科技大学同济医学院附属协和医院	秋水仙碱在制备用于增加冠状动脉斑块纤维帽厚度药物中的应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3173876A (en)	1960-05-27	1965-03-16	John C Zobrist	Cleaning methods and compositions
US3276586A (en)	1963-08-30	1966-10-04	Rosaen Filter Co	Indicating means for fluid filters
US3546142A (en)	1967-01-19	1970-12-08	Amicon Corp	Polyelectrolyte structures
US3541006A (en)	1968-07-03	1970-11-17	Amicon Corp	Ultrafiltration process
US3541005A (en)	1969-02-05	1970-11-17	Amicon Corp	Continuous ultrafiltration of macromolecular solutions
US4285987A (en)	1978-10-23	1981-08-25	Alza Corporation	Process for manufacturing device with dispersion zone
US5171217A (en)	1991-02-28	1992-12-15	Indiana University Foundation	Method for delivery of smooth muscle cell inhibitors
US7820383B2 (en)	1997-03-10	2010-10-26	Interleukin Genetics, Inc.	Method for diagnosing myocardial infarction
JP2000034224A (ja)	1998-05-11	2000-02-02	Freunt Ind Co Ltd	徐放性錠剤、その添加剤組成物及びそれらの製造方法
US20020169145A1 (en)	1998-10-14	2002-11-14	Rajen Shah	Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
EP1239856A1 (en)	1999-12-22	2002-09-18	Pharmacia Corporation	Sustained-release formulation of a cyclooxygenase-2 inhibitor
EA008224B1 (ru)	2001-03-13	2007-04-27	Пенвест Фармасьютикалз Ко.	Хронотерапевтические дозированные формы
US8853266B2 (en)	2001-12-06	2014-10-07	University Of Tennessee Research Foundation	Selective androgen receptor modulators for treating diabetes
US20030144203A1 (en)	2001-12-19	2003-07-31	Voyager Pharmaceutical Corporation	Methods for slowing senescence and treating and preventing diseases associated with senescence
CN1606652A (zh)	2001-12-21	2005-04-13	未来概念公司	用于充气构件的压杆
SE0401031D0 (sv)	2004-04-22	2004-04-22	Duocort Ab	A new glucocorticoid replacement therapy
US20060045865A1 (en)	2004-08-27	2006-03-02	Spherics, Inc.	Controlled regional oral delivery
WO2006063091A2 (en)	2004-12-06	2006-06-15	Ronald Freudenberger	Use of oxypurinol as an inhibitor of anti-neoplastic agent-induced cardiotoxicity
US20060171948A1 (en) *	2005-02-02	2006-08-03	Weinstein Steven P	Methods of using IL-1 antagonists to reduce C-reactive protein
US20060286108A1 (en) *	2005-06-16	2006-12-21	Bell Katherine A	Topical compositions for the treatment of chronic wounds
CN1939290A (zh) *	2005-09-29	2007-04-04	陆宪光	秋水仙碱及它的衍生物的医学用途
US20090215687A1 (en) *	2005-10-21	2009-08-27	Cornell Research Foundation, Inc.	Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
EP2023874A4 (en)	2006-06-02	2009-07-08	Bioseek Inc	METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS
ATE517619T1 (de)	2006-06-09	2011-08-15	Ucb Pharma Gmbh	Stabilisierte pharmazeutische zusammensetzung mit fesoterodin
WO2008131192A2 (en) *	2007-04-18	2008-10-30	The Trustees Of Columbia University In The City Of New York	Crystalline cholestrol and prevention of atherosclerosis
US20090093548A1 (en)	2007-10-05	2009-04-09	Mutual Pharmaceutical Company, Inc	Colchine compositions and methods
CN101485638A (zh)	2008-01-18	2009-07-22	普尔药物科技开发（深圳）有限公司	秋水仙碱双层渗透泵控释片及其制备方法
CN101485637B (zh)	2008-01-18	2011-03-30	普尔药物科技开发（深圳）有限公司	秋水仙碱骨架控释片或胶囊
US20090299155A1 (en)	2008-01-30	2009-12-03	Dexcom, Inc.	Continuous cardiac marker sensor system
CN101536990A (zh)	2008-03-18	2009-09-23	普尔药物科技开发（深圳）有限公司	秋水仙碱胃漂浮缓释片及其制备方法
WO2009151770A2 (en)	2008-04-15	2009-12-17	Mutual Pharmaceutical Company, Inc.	Colchicine solid-state forms; methods of making; and methods of use thereof
ES2356494T3 (es)	2008-05-28	2011-04-08	Indena S.P.A.	Procedimiento para la glucosidación de colchicina y tiocolchicina.
DE102008047910A1 (de)	2008-09-19	2010-03-25	Molkerei Meggle Wasserburg Gmbh & Co. Kg	Tablettierhilfsstoff auf Laktose- und Cellulosebasis
GB0819287D0 (en)	2008-10-22	2008-11-26	Univ Bradford	Compounds
CN101732274A (zh)	2008-11-19	2010-06-16	普尔药物科技开发（深圳）有限公司	秋水仙碱双层缓释片及其制备方法
US7820681B1 (en)	2009-01-14	2010-10-26	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
US8945622B2 (en)	2009-03-09	2015-02-03	Council Of Scientific And Industrial Research	Sustained release composition of therapeutic agent
EP2435403A4 (en)	2009-05-27	2015-04-01	Takeda Pharmaceuticals Usa Inc	THIOCOLCHICINE DERIVATIVES AND MANUFACTURING AND USE METHOD THEREFOR
US20110046228A1 (en)	2009-08-20	2011-02-24	Mutual Pharmaceutical Company, Inc.	Methods for administration of colchicine with grapefruit juice
US20110046227A1 (en) *	2009-08-21	2011-02-24	Mutual Pharmaceutical Company, Inc.	Methods for concomitant administration of colchicine and a second active agent
DK2470499T3 (da)	2009-08-26	2019-09-23	Alberta Health Services	Nye colchicin-derivativer, fremgangsmåder og anvendelse deraf
ES2689107T3 (es)	2009-11-13	2018-11-08	Astrazeneca Ab	Formulaciones de tabletas bicapa
US20110178180A1 (en)	2010-01-18	2011-07-21	Kurt Nielsen	Deuterium-enriched colchicine, thiocolchicine, and derivatives thereof; methods of preparation; and use thereof
EP2481411A1 (en)	2011-01-27	2012-08-01	Ratiopharm GmbH	Oral dosage forms for modified release comprising the JAK3 inhibitor tasocitinib
SG11201406495UA (en)	2012-04-13	2014-11-27	Cymabay Therapeutics Inc	Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent
MX393493B (es)	2012-11-02	2025-03-21	Murray & Poole Entpr Ltd	Tratamiento o prevención de eventos cardiovasculares.
AU2014255434B2 (en) *	2013-04-16	2018-11-08	Murray And Poole Enterprises Limited	Sustained-release formulations of colchicine and methods of using same

2013
- 2013-11-01 MX MX2020009511A patent/MX393493B/es unknown
- 2013-11-01 EP EP21185610.9A patent/EP3964205A1/en active Pending
- 2013-11-01 AU AU2013337605A patent/AU2013337605B2/en active Active
- 2013-11-01 MY MYPI2015001141A patent/MY177898A/en unknown
- 2013-11-01 WO PCT/AU2013/001261 patent/WO2014066944A1/en not_active Ceased
- 2013-11-01 PL PL13851803T patent/PL2914255T3/pl unknown
- 2013-11-01 NZ NZ707640A patent/NZ707640A/en unknown
- 2013-11-01 SG SG10201703586PA patent/SG10201703586PA/en unknown
- 2013-11-01 SI SI201331938T patent/SI2914255T1/sl unknown
- 2013-11-01 NZ NZ747657A patent/NZ747657A/en unknown
- 2013-11-01 DK DK13851803.0T patent/DK2914255T3/da active
- 2013-11-01 ES ES13851803T patent/ES2900740T3/es active Active
- 2013-11-01 CN CN201380069087.1A patent/CN104918613B/zh active Active
- 2013-11-01 KR KR1020247015728A patent/KR102858016B1/ko active Active
- 2013-11-01 HR HRP20211644TT patent/HRP20211644T1/hr unknown
- 2013-11-01 KR KR1020257035081A patent/KR20250154562A/ko active Pending
- 2013-11-01 HU HUE13851803A patent/HUE056810T2/hu unknown
- 2013-11-01 KR KR1020257029720A patent/KR20250138815A/ko active Pending
- 2013-11-01 KR KR1020237010301A patent/KR102666548B1/ko active Active
- 2013-11-01 SG SG11201503440UA patent/SG11201503440UA/en unknown
- 2013-11-01 PT PT13851803T patent/PT2914255T/pt unknown
- 2013-11-01 CN CN201810381444.2A patent/CN108721265B/zh active Active
- 2013-11-01 CA CA2894417A patent/CA2894417C/en active Active
- 2013-11-01 BR BR112015010063-5A patent/BR112015010063B1/pt active IP Right Grant
- 2013-11-01 KR KR1020217004356A patent/KR20210020170A/ko not_active Ceased
- 2013-11-01 MX MX2015005637A patent/MX375082B/es active IP Right Grant
- 2013-11-01 KR KR1020217042615A patent/KR20220001518A/ko not_active Ceased
- 2013-11-01 JP JP2015539999A patent/JP6356684B2/ja active Active
- 2013-11-01 LT LTEPPCT/AU2013/001261T patent/LT2914255T/lt unknown
- 2013-11-01 EA EA201500484A patent/EA032515B1/ru unknown
- 2013-11-01 EP EP13851803.0A patent/EP2914255B1/en active Active
- 2013-11-01 KR KR1020157014487A patent/KR20150102969A/ko not_active Ceased
- 2013-11-01 US US14/440,147 patent/US10265281B2/en active Active
2015
- 2015-01-22 US US14/603,049 patent/US9744144B2/en active Active
- 2015-01-22 US US14/603,085 patent/US20150196514A1/en not_active Abandoned
- 2015-04-29 IL IL238519A patent/IL238519B/en active IP Right Grant
- 2015-04-30 CL CL2015001154A patent/CL2015001154A1/es unknown
2017
- 2017-07-28 US US15/663,148 patent/US10206891B2/en active Active
2018
- 2018-05-25 AU AU2018203715A patent/AU2018203715B2/en active Active
- 2018-12-21 US US16/229,504 patent/US20190117598A1/en not_active Abandoned
2019
- 2019-04-22 US US16/390,606 patent/US10842761B2/en active Active
- 2019-08-26 US US16/550,692 patent/US10842762B2/en active Active
- 2019-09-19 AU AU2019232879A patent/AU2019232879B2/en active Active
2020
- 2020-11-19 US US16/952,617 patent/US11666545B2/en active Active
- 2020-11-24 US US17/103,562 patent/US11026899B2/en active Active
- 2020-11-24 US US17/103,683 patent/US11026901B2/en active Active
- 2020-11-24 US US17/103,660 patent/US11026900B2/en active Active
2021
- 2021-12-09 AU AU2021282491A patent/AU2021282491B2/en active Active
2023
- 2023-05-08 US US18/144,470 patent/US11944594B2/en active Active
- 2023-05-08 US US18/144,528 patent/US11944595B2/en active Active
- 2023-09-12 US US18/367,412 patent/US12280025B2/en active Active
- 2023-09-12 US US18/367,405 patent/US12233035B2/en active Active
2024
- 2024-04-10 US US18/631,405 patent/US12364675B2/en active Active
- 2024-07-25 AU AU2024205084A patent/AU2024205084B2/en active Active
2025
- 2025-01-20 US US19/032,166 patent/US20250381156A1/en active Pending
- 2025-06-11 US US19/234,427 patent/US20250302776A1/en active Pending

Also Published As

Publication number	Publication date
AU2018203715A1 (en)	2018-06-21
DK2914255T3 (da)	2021-10-25
US10842762B2 (en)	2020-11-24
AU2018203715B2 (en)	2019-06-20
US11944594B2 (en)	2024-04-02
EP2914255A1 (en)	2015-09-09
AU2024205084A1 (en)	2024-08-15
US20190314303A1 (en)	2019-10-17
JP2015535264A (ja)	2015-12-10
US20250302776A1 (en)	2025-10-02
US10842761B2 (en)	2020-11-24
US20210069132A1 (en)	2021-03-11
US20170326083A1 (en)	2017-11-16
US20150196513A1 (en)	2015-07-16
CN104918613A (zh)	2015-09-16
HUE056810T2 (hu)	2022-03-28
US11666545B2 (en)	2023-06-06
IL238519A0 (en)	2015-06-30
NZ707640A (en)	2019-03-29
KR20210020170A (ko)	2021-02-23
US20230414539A1 (en)	2023-12-28
US9744144B2 (en)	2017-08-29
US11026899B2 (en)	2021-06-08
CL2015001154A1 (es)	2015-12-18
MX2015005637A (es)	2016-02-03
KR102666548B1 (ko)	2024-05-21
AU2013337605A1 (en)	2015-05-21
SI2914255T1 (sl)	2021-12-31
EP2914255A4 (en)	2016-06-29
US20230270698A1 (en)	2023-08-31
BR112015010063A2 (pt)	2018-12-18
MX2020009511A (es)	2022-05-09
US20210069133A1 (en)	2021-03-11
US20250381156A1 (en)	2025-12-18
CA2894417C (en)	2019-09-10
CN108721265B (zh)	2022-12-02
US20250082590A1 (en)	2025-03-13
EA032515B1 (ru)	2019-06-28
NZ747657A (en)	2019-12-20
US11026900B2 (en)	2021-06-08
US20150196514A1 (en)	2015-07-16
CN108721265A (zh)	2018-11-02
KR20230049751A (ko)	2023-04-13
AU2019232879B2 (en)	2021-09-09
WO2014066944A1 (en)	2014-05-08
EP3964205A1 (en)	2022-03-09
US11944595B2 (en)	2024-04-02
US20190374487A1 (en)	2019-12-12
KR20240074883A (ko)	2024-05-28
AU2021282491B2 (en)	2024-05-09
CA2894417A1 (en)	2014-05-08
JP6356684B2 (ja)	2018-07-11
KR102858016B1 (ko)	2025-09-11
KR20250154562A (ko)	2025-10-28
CN104918613B (zh)	2018-05-25
PL2914255T3 (pl)	2022-01-03
BR112015010063B1 (pt)	2021-11-09
EP2914255B1 (en)	2021-07-21
US20210069131A1 (en)	2021-03-11
AU2024205084B2 (en)	2026-03-26
KR20220001518A (ko)	2022-01-05
KR20250138815A (ko)	2025-09-22
US20190117598A1 (en)	2019-04-25
US11026901B2 (en)	2021-06-08
US20240082179A1 (en)	2024-03-14
US20210077432A1 (en)	2021-03-18
ES2900740T3 (es)	2022-03-18
MX375082B (es)	2025-03-06
SG11201503440UA (en)	2015-06-29
AU2013337605B2 (en)	2018-03-01
EA201500484A1 (ru)	2015-10-30
IL238519B (en)	2020-04-30
US10206891B2 (en)	2019-02-19
KR20150102969A (ko)	2015-09-09
MY177898A (en)	2020-09-24
US12280025B2 (en)	2025-04-22
HRP20211644T1 (hr)	2022-02-04
US12364675B2 (en)	2025-07-22
US10265281B2 (en)	2019-04-23
US20230270697A1 (en)	2023-08-31
AU2021282491A1 (en)	2022-01-06
MX393493B (es)	2025-03-21
US12233035B2 (en)	2025-02-25
AU2019232879A1 (en)	2019-10-10
SG10201703586PA (en)	2017-06-29
US20150272912A1 (en)	2015-10-01
PT2914255T (pt)	2021-10-27

Publication	Publication Date	Title
LTC2785706I2 (lt)	2023-07-10	Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
LT2887944T (lt)	2022-01-10	Alopregnanolonas, skirtas atsparios epileptinės būklės gydymui
IL247452A0 (en)	2016-11-30	Compounds for treatment of complement mediated disorders
IL262879A (en)	2018-12-31	Modified seraphins for the treatment of bleeding disorders
CL2015000873A1 (es)	2015-08-14	Métodos para el tratamiento del síndrome de alport.
LT3470063T (lt)	2025-02-10	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
LT3292875T (lt)	2020-08-25	Kompozicijos ir būdai, skirti ligų gydymui
SI3626270T1 (sl)	2024-03-29	Zdravljenje srčno-žilnih bolezni
GB201219873D0 (en)	2012-12-19	Diverticulitis treatment
HUE037179T2 (hu)	2018-08-28	Gyógyászati kompozíciók izom-rendellenességek kezelésére
IL246721B (en)	2018-12-31	History of 5-benzylisoquinoline for the treatment of cardiovascular diseases
EP3142736A4 (en)	2018-02-14	Directing treatment of cardiovascular events by non-specialty caregivers
HUS2000037I1 (hu)	2020-10-28	Triazinok Protozoa okozta betegségek kezelésére
DK2925317T3 (da)	2019-11-18	CFTR-korrektor til behandling af genetiske forstyrrelser, der påvirker tværstribet muskel
LT2812013T (lt)	2019-07-10	Kompozicija, skirta džs gydymui
SG11201708198SA (en)	2017-11-29	Methods for the treatment of cardiovascular disorders
ITRM20120405A1 (it)	2014-02-10	Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac
DK3919060T3 (da)	2025-09-15	Ecopipam til behandling af Tourettes syndrom
SMT201600268B (it)	2016-08-31	Composizione per il trattamento delle neuropatie
IT1403438B1 (it)	2013-10-17	Rivestimento del manubrio.
EP2999464A4 (en)	2017-01-11	Methods and compositions for the disruption of biofilms and treatment of disorders characterized by the presence of biofilms
ITUB20155450A1 (it)	2017-05-11	Composizione per il trattamento delle dermatiti.
GB201320014D0 (en)	2013-12-25	Treatment of cardiovascular disease
GB201219092D0 (en)	2012-12-05	Treatment of cardiovascular disease
GB201521542D0 (en)	2016-01-20	Methods for the treatment of cardiovascular disorders